Local perfusion of the tumor necrosis factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss

Audiology and Neurotology

Volumn 11, Issue 6, 2006, Pages 357-365

  Van Wijk, F ^a   Staecker, H ^b   Keithley, E ^c   Lefebvre, P P ^a,d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF KANSAS   (United States)

^c Department of Otolaryngology ^*  (United States)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Autoimmune hearing loss; Tumor necrosis factor

Indexed keywords

INFLIXIMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUDITORY THRESHOLD; AUTOIMMUNE INNER EAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COCHLEA FENESTRA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; IMPLANTATION; INFUSION SYSTEM; INNER EAR DISEASE; LOCAL THERAPY; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERCEPTION DEAFNESS; PERFUSION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; AUTOIMMUNE DISEASES; AUTOIMMUNITY; FEMALE; GLUCOCORTICOIDS; HEARING LOSS, SENSORINEURAL; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; ROUND WINDOW; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; TYMPANIC MEMBRANE;

EID: 33750277793     PISSN: 14203030     EISSN: 14219700     Source Type: Journal    
DOI: 10.1159/000095897     Document Type: Article

References (32)

1. Banerjee A, Parnes LS: Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005;26:878-881.
2. Boulassel MR, Deggouj N, Tomasi JP, Gersdorff M: Inner ear autoantibodies and their targets in patients with autoimmune inner ear diseases. Acta Otolaryngol 2001;121:28-34.
3. Cao MY, Dupriez VJ, Rider MH, Deggouj N, Gersdorff MC, Rousseau GG, Tomasi JP: Myelin protein Po as a potential autoantigen in autoimmune inner ear disease. FASEB J 1996;10:1635-1640.
4. Chandrasekhar SS: Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22:18-23.
5. Chen MC, Harris JP, Keithley EM: Immunohistochemical analysis of proliferating cells in a sterile labyrinthitis animal model. Laryngoscope 1998;108:651-656.
6. Cohen S, Shoup A, Weisman MH, Harris J: Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol 2005;26:903-907.
7. Froehlich F, Fried M, Gonvers JJ, Saraga E, Thorens J, Pecoud A: Association of Crohn's disease and Cogan's syndrome. Dig Dis Sci 1994;39:1134-1137.
8. Harris JP, Ryan AF: Effect of a middle ear immune response on inner ear antibody levels. Ann Otol Rhinol Laryngol 1985;94:202-206.
9. Harris JP, Sharp PA: Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope 1990;100:516-524.
10. Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE: Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003;290:1875-1883.
11. Herr BD, Marzo SJ: Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132:527-531.
12. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R: Improved functional ability in patients with rheumatoid arthritis - long-term treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001;28:1983-1991.
13. Keithley EM, Ryan AF, Harris JP: Role of the round window membrane in middle ear immune responses. Acta Otolaryngol Suppl 1989;457:139-143.
14. Lefebvre PP, Staecker H: Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002;122:698-702.
15. Matteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CL, Strome SE, McDonald TJ: Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Rheum 2001;45:146-150.
16. Matteson EL, Tirzaman O, Facer GW, Fabry DA, Kasperbauer J, Beatty CW, McDonald TJ: Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000;109:710-714.
17. McCabe BF: Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;113:526-530.
18. Nash PT, Florin TH: Tumour necrosis factor inhibitors. Med J Aust 2005;183:205-208.
19. Parnes LS, Sun AH, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109:1-17.
20. Ruckenstein MJ: Autoimmune inner ear disease. Curr Opin Otolaryngol Head Neck Surg 2004;12:426-430.
21. Ryan AF, Harris JP, Keithley EM: Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol Suppl 2002;548:38-43.
22. Ryan AF, Keithley EM, Harris JP: Autoimmune inner ear disorders. Curr Opin Neurol 2001;14:35-40.
23. Salley LH Jr, Grimm M, Sismanis A, Spencer RF, Wise CM: Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients. J Rheumatol 2001;28:1037-1040.
24. Sandborn WJ: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:501-505.
25. Siddiqui MA, Scott LJ: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005;65:2179-2208.
26. Sismanis A, Wise CM, Johnson GD: Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-152.
27. Soliman AM, Zanetti F: Improvements of a method for testing autoantibodies in sensorineural hearing loss. Adv Otorhinolaryngol 1988;39:13-17.
28. Staecker H, Lefebvre PP: Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report. Acta Otolaryngol 2002;122:684-687.
29. ten Cate WJ, Bachor E: Autoimmune-mediated sympathetic hearing loss: a case report. Otol Neurotol 2005;26:161-165.
30. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785.
31. Wang X, Truong T, Billings PB, Harris JP, Keithley EM: Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol 2003;24:52-57.
32. Welling DB: Clinical evaluation and treatment of immune-mediated inner ear disease. Ear Nose Throat J 1996;75:301-305.